A concept and design for a revolutionary medical device aimed at critically ill patients
Continuous monitoring and correction of blood parameters. Without loss of blood and without drugs
Hemocorr is a patented concept and design — with patents granted in the United States and India — for an extracorporeal platform (just like dialysis and other similar devices) that would read dozens of substances circulating in the blood at the same time, in real time, and bring the ones that are out of range back to target, using physical and chemical capture instead of medication.
We monitor the heart continuously.
We barely monitor the blood at all.
Every intensive care unit runs three monitors that never switch off: an ECG, a blood pressure cuff, and a pulse oximeter. These exist because the heart, circulation, and breathing can change in seconds — and delay is fatal.
But the blood — the medium through which every organ in the body communicates with every other organ — is still checked only a few times a day. A tube is drawn, sent to a laboratory, and the results come back hours later. In a patient who can deteriorate in minutes, those results are always behind the patient's actual state.
More than 5 million patients are admitted to intensive care units in the United States alone every year. ICU mortality ranges from 8% to 19% despite best current care. Not all of those deaths are preventable — but some are the result of changes that were not caught in time, or corrected with drugs that created their own complications.
Blood is the body's internal messaging system. Every organ sends and receives dozens of chemical signals through the bloodstream. In serious illness, these signals swing rapidly — sometimes within minutes. Watching them is like trying to follow a film from a handful of still photographs taken hours apart.
What every ICU already watches — and what falls through
Every ICU has three monitors that never switch off. Everything else about the blood's chemistry is checked by sending a sample to a laboratory, hours apart. Continuous monitoring of levels of multiple molecules circulating in the blood is not possible at present.
What existing approaches cannot do
In-body sensors
Each watches one molecule at a time and is vulnerable to tissue interference, protein fouling, and clot formation on its surface. Deploying dozens of them on or inside a patient is neither safe nor practical.
Dialysis & adsorption devices
Remove by molecular size or non-specific binding — not by target. No real-time feedback on whether correction is working. Cannot address more than one or two molecules per session.
Drugs
Critically ill patients receive an average of 25–35 medications per ICU stay — roughly twice as many as general-ward patients. Dosing must be estimated; interactions compound; adverse effects scale with how sick the patient already is.
Hemocorr — designed to close all three gaps at once
Continuous multi-analyte monitoring, selective drug-free correction, and real-time feedback — in a single extracorporeal loop.
Three things medicine currently cannot do — simultaneously, but Hemocorr will
Watch the blood continuously
Dozens of molecules and ions — glucose, lactate, electrolytes, inflammatory markers, coagulation factors — monitored in real time without interruption and without the patient losing a drop of blood. Not a snapshot every few hours. A continuous film.
Correct without drugs
When a molecule is too high, purpose-designed capturing particles — injected into an external circuit, never into the patient — bind to exactly one target and are swept out by a magnetic field. No drug enters the body. Nothing unintended is removed. Precise, selective, and verifiable.
Generate data medicine has never had
Minute-by-minute blood chemistry profiles across dozens of analytes in seriously ill patients — the foundational dataset that AI prognostic models need and cannot currently access. Hemocorr would not just treat patients. It would build the quantitative understanding of how critical illness unfolds.
Cause of death is easy to name.
Mechanism is a different matter.
We can write "cardiac arrhythmia" on a death certificate with confidence. What we cannot explain — in quantitative terms — is the precise molecular sequence that led to it: the exact concentrations, in what order, of which electrolytes, hormones, cytokines, and inflammatory markers that drove the heart to its final failure.
The reason is simple: we have never watched it happen. We have snapshots, hours apart. Hemocorr would, for the first time, produce the continuous data needed to trace that molecular story — and to build models that could predict it in advance, in living patients, before it became irreversible.
Every component already exists.
Hemocorr is a patented concept and design — not yet a working device. But every individual subsystem it would need already exists in validated clinical or laboratory use:
- Extracorporeal circulation — dialysis machines have used this for decades
- Plasma fractionation by centrifugation — standard procedure in blood banks worldwide
- Multi-analyte optical & electrochemical sensing — demonstrated in research and clinical benchtop instruments
- Magnetic nanoparticle capture — validated in laboratory and early clinical settings
The innovation is the integration of these components on one closed-loop platform. The IP protecting that integration is already granted.
How Hemocorr would work
Read Hemocorr your way
Pick the perspective that fits
Patients & families
What Hemocorr is, why it matters, and what it might one day mean for critically ill patients — no technical background needed.
Read the plain-language guide ClinicalClinicians & doctors
The monitoring gap, the drug burden, cause versus mechanism of death, and what real-time blood chemistry data would change in the ICU.
Read the clinical brief TechnicalEngineers & scientists
The system architecture, sensor limitations, plasma fractionation, magnetic capture chemistry, and the mathematical case for continuous data.
Read the technical brief BusinessInvestors
Market context across six industries, IP position, competitive landscape, and what Hemocorr needs to move from patent to prototype.
Read the investment overviewDr. Bal Chander
An alumnus of the All India Institute of Medical Sciences (AIIMS), New Delhi — India's premier medical institution — and Professor of Pathology at Dr. Rajendra Prasad Government Medical College, Himachal Pradesh.
The idea for Hemocorr began in the postmortem room: measuring hormone concentrations inside organs that appeared histologically normal and finding variation that no blood test would ever have revealed. That finding, combined with years of cross-disciplinary thinking, produced the architecture now protected by two granted patents.
The work is entirely self-funded. Dr. Chander is the sole inventor and sole patent owner, with no existing licensing agreements.
Patent records
US Patent
US 12,350,039 B2 — Blood analysis system
Inventor: Bal Chander · Granted July 8, 2025
Indian Patent
IN 567865 — Blood analysis system
Inventor: Bal Chander · Granted
Search at Indian Patent Office ↗PCT / WIPO
WO 2020/230153
PCT/IN2020/050415 · EPO: 41/44 claims novel & inventive
View WIPO patentscope ↗